

U.S. SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended **March 31, 2008**

000-28745
(Commission File No.)

NATIONAL SCIENTIFIC CORPORATION
(Name of Registrant as Specified in its Charter)

Texas
(State of Incorporation)

86-0837077
(I.R.S. Employer Identification No.)

8361 E. Evans Road, Suite 106
Scottsdale, AZ 85260-3617
(Address of Principal Executive Offices)

(480) 948-8324
(Issuers Telephone Number, Including Area Code)

Securities registered under Section 12(b) of the Exchange Act:
Preferred Stock, \$0.10 par value

Securities registered under Section 12(g) of the Exchange Act:
Common Stock, \$0.01 par value

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of "large accelerated filer", "accelerated filer", and "smaller reporting company" in Rule 12b-2 of the Exchange Act (check one):

Large accelerated filer Accelerated filer Non-accelerated filer Smaller reporting company

Indicate by check mark if the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

There were 122,332,913 shares of Common Stock, par value \$.01 per share, outstanding at May 9, 2008.

[Table of Contents](#)

NATIONAL SCIENTIFIC CORPORATION
FORM 10-Q
TABLE OF CONTENTS

	<u>Page</u>	
Part I	Financial Information	3
Item 1.	Financial Statements (unaudited)	3
	Condensed Balance Sheets - As of March 31, 2008 (Unaudited) and September 30, 2007	3
	Condensed Statements of Operations (Unaudited) - Three and six months ended March 31, 2008 and 2007	4
	Condensed Statements of Cash Flows (Unaudited) - Six months ended March 31, 2008 and 2007	5
	Condensed Statement of Changes in Shareholders' Deficit (Unaudited) - Six months ended March 31, 2008	6
	Notes to Condensed Financial Statements	7
Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	16
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	21
Item 4T.	Controls and Procedures	21
Part II	Other Information	21
Item 1.	Legal Proceedings	21
Item 1A.	Risk Factors	22
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	22
Item 3.	Defaults Upon Senior Securities	22
Item 4.	Submission of Matters to a Vote of Security Holders	22
Item 5.	Other Information	22
Item 6.	Exhibits	22
Signatures		23
Exhibit 31 - Certification Pursuant to Section 302 of the Sarbanes-Oxley Act		
Exhibit 32 - Certification Pursuant to Section 906 of the Sarbanes-Oxley Act		

PART 1 - FINANCIAL INFORMATION**Item 1. Financial Statements****NATIONAL SCIENTIFIC CORPORATION****Condensed Balance Sheets**

ASSETS	March 31, 2008 (Unaudited)	September 30, 2007 (Audited)
Current Assets:		
Cash and cash equivalents	\$ 2,322	\$ 85,887
Trade receivables, net	47,392	6,216
Inventory, net	15,340	22,900
Other assets	12,633	68
Total current assets	77,687	115,071
Property and equipment, net	415	622
Deposits	2,340	2,340
Deferred financing costs, net	12,400	14,800
Total assets	\$ 92,842	\$ 132,833
LIABILITIES AND SHAREHOLDERS' DEFICIT		
Current Liabilities:		
Accounts payable - related parties	\$ -	\$ 419
Accounts payable - other	196,245	195,004
Accrued expenses	1,032,284	883,400
Due to factors	21,912	2,602
Notes payable - related party	144,876	161,300
Notes payable - other	79,875	80,875
Total current liabilities	1,475,192	1,323,600
Notes payable, less current portion, net of discount and beneficial conversion feature of \$31,792 at March 31, 2008 and \$37,945 at September 30, 2007	143,208	137,055
Total liabilities	1,618,400	1,460,655
Commitments and contingencies	-	-
Shareholders' deficit:		
Preferred stock, par value \$0.10; 4,000,000 shares authorized, none issued and outstanding	-	-
Common stock, par value \$0.01; 187,000,000 shares authorized, and shares issued and outstanding of 122,332,913 at March 31, 2008 and 121,995,835 at September 30, 2007	1,223,330	1,219,959
Additional paid-in capital	22,709,408	22,693,696
Accumulated deficit	(25,458,296)	(25,241,477)
Total shareholders' deficit	(1,525,558)	(1,327,822)
Total liabilities and shareholder's deficit	\$ 92,842	\$ 132,833

The accompanying notes are an integral part of these condensed financial statements.

NATIONAL SCIENTIFIC CORPORATION

Condensed Statements of Operations
(Unaudited)

	Three months ended		Six months ended	
	March 31		March 31	
	<u>2008</u>	<u>2007</u>	<u>2008</u>	<u>2007</u>
Revenues	\$ 156,216	\$ 46,500	\$ 371,755	\$ 184,716
Cost of Sales	<u>83,033</u>	<u>21,510</u>	<u>206,473</u>	<u>93,485</u>
Gross profit	<u>73,183</u>	<u>24,990</u>	<u>165,282</u>	<u>91,231</u>
Costs and expenses				
Salaries and benefits	71,055	62,529	137,293	133,851
Research and development	41,457	40,834	84,708	84,287
Stock compensation	14	4,931	14,319	7,931
Other	<u>62,608</u>	<u>34,330</u>	<u>98,761</u>	<u>69,273</u>
Total costs and expenses	<u>175,134</u>	<u>142,624</u>	<u>335,081</u>	<u>295,342</u>
Loss from operations	<u>(101,951)</u>	<u>(117,634)</u>	<u>(169,799)</u>	<u>(204,111)</u>
Other income (expense)				
Other income	–	25,000	–	25,740
Interest expense	(21,772)	(82,907)	(44,620)	(118,613)
Amortization of deferred financing costs	<u>(1,200)</u>	<u>(1,200)</u>	<u>(2,400)</u>	<u>(2,400)</u>
	<u>(22,972)</u>	<u>(59,107)</u>	<u>(47,020)</u>	<u>(95,273)</u>
Loss before income taxes	(124,923)	(176,741)	(216,819)	(299,384)
Income tax expense	<u>–</u>	<u>–</u>	<u>–</u>	<u>–</u>
Net loss	<u>\$ (124,923)</u>	<u>\$ (176,741)</u>	<u>\$ (216,819)</u>	<u>\$ (299,384)</u>
Net loss per common share, basic and diluted	<u>\$ (0.00)</u>	<u>\$ (0.00)</u>	<u>\$ (0.00)</u>	<u>\$ (0.00)</u>
Weighted average number of shares outstanding	<u>122,303,826</u>	<u>102,116,638</u>	<u>122,230,098</u>	<u>100,595,808</u>

The accompanying notes are an integral part of these condensed financial statements.

NATIONAL SCIENTIFIC CORPORATION

Condensed Statements of Cash Flows
(Unaudited)

	Six months ended	
	March 31,	
	2008	2007
Cash flows from operating activities:		
Net loss	\$ (216,819)	\$ (299,384)
Adjustments to reconcile net loss to net cash used in operating activities:		
Depreciation	207	207
Stock issued for services	2,000	3,000
Stock options issued for services	12,319	4,931
Stock issued to cure default of note payable	–	66,000
Warrant expense	–	871
Amortization of deferred financing costs	2,400	2,400
Amortization of debt discount	5,160	5,160
Amortization of beneficial conversion feature	993	993
Changes in assets and liabilities:		
Decrease (increase) in inventory, net	7,560	(2,136)
Increase in receivables, net	(41,176)	(6,147)
Decrease (increase) in other assets and deposits	(12,565)	4,083
Increase in accounts payable and accrued expenses	154,470	107,591
Net cash used in operating activities	<u>(85,451)</u>	<u>(112,431)</u>
Cash flows from financing activities:		
Increase in notes payable	–	20,725
Repayment of notes payable	(17,424)	(12,025)
Net proceeds from factors	19,310	(35,520)
Proceeds from issuance of common stock	–	109,800
	<u>1,886</u>	<u>82,980</u>
Net decrease in cash and cash equivalents	(83,565)	(29,451)
Cash and cash equivalents, beginning of period	85,887	43,899
Cash and cash equivalents, end of period	<u>\$ 2,322</u>	<u>\$ 14,448</u>
Supplementary Disclosure of Cash Flow Information:		
Cash paid for interest	<u>\$ 7,407</u>	<u>\$ 11,860</u>
Conversion of accounts payable and accrued expenses to equity	<u>\$ 5,000</u>	<u>\$ 45,000</u>
Conversion of notes payable and accrued expenses to equity	<u>\$ –</u>	<u>\$ 60,200</u>

The accompanying notes are an integral part of these condensed financial statements.

NATIONAL SCIENTIFIC CORPORATION

**Condensed Statement of Changes in Shareholders' Deficit
For the Six months Ended March 31, 2008
(Unaudited)**

	<u>Common Stock</u>		<u>Additional</u>	<u>Accumulated</u>	
	<u>Number of</u>	<u>Par Value</u>	<u>Paid-In</u>	<u>Deficit</u>	<u>Total</u>
	<u>Shares</u>		<u>Capital</u>		
Balance at September 30, 2007	121,995,835	\$ 1,219,959	\$ 22,693,696	\$ (25,241,477)	\$ (1,327,822)
Stock issued for services					
Price per share:					
\$0.0288	34,722	347	653	—	1,000
\$0.0191	52,356	524	476	—	1,000
Stock options granted	—	—	12,083	—	12,083
Stock issued in exchange of accrued expenses					
for:					
\$0.0200	250,000	2,500	2,500	—	5,000
Net loss for the six months ended March 31, 2008	—	—	—	(216,819)	(216,819)
Balance at March 31, 2008	<u>122,332,913</u>	<u>\$ 1,223,330</u>	<u>\$ 22,709,408</u>	<u>\$ (25,458,296)</u>	<u>\$ (1,525,558)</u>

The accompanying notes are an integral part of these condensed financial statements.

NATIONAL SCIENTIFIC CORPORATION

NOTES TO FINANCIAL STATEMENTS

March 31, 2008

(Unaudited)

1. Summary of Significant Accounting Policies and Use of Estimates

Nature of Business

Our primary business involves the research, development, manufacture, and sale of hardware and software computer based products and devices that span a range of industries. The majority of our products are mobile computers configured as digital video recording devices with location determining and tracking capabilities. These devices typically use small powerful mobile computers, in conjunction with equally small portable radios to establish, record and report the physical location of people and objects to which these devices are attached. Our location technologies typically use Global Positioning System (GPS) technology to determine position. They also use small computers in conjunction with video cameras and other sensors to record incidents on mobile systems, especially school buses. We also have other products that use non-GPS technology to establish and then report position. We refer to our location-determining devices as our location tracking products, or as location tools products.

Our primary customer focus for these location-tracking products is the safety market, related in many cases to the safety of school age children. Our products and services help our customers keep better track of their children. Our products are also used to keep track of adults, and as well to track and monitor physical assets, such as equipment or vehicles. Our location tracking products are often sold as an integrated system, by using them in conjunction with software that displays maps and other pertinent information.

Prior to 2002 we developed electronic component products, some of which are used in radio equipment, and some of which have other applications in the electronics field, such as in the memory systems of personal computers. Many of these electronic component products have been issued U.S. patents. We focused extensively on developing these products and patenting them from 1996 through early 2002, with the objective of licensing these products to other electronic companies. In early 2002, due to market conditions, our focus shifted away from further development of our electronic component products, but we continue to explore licensing opportunities for our component products.

Since 2002, we began to focus on applications of electronic devices in the location tools market. From 2002 through 2005, we were primarily engaged in product development and market research and testing. During fiscal year 2005, the Company increased its focus on its Travado IBUS™, a location product that entered the market in March 2005. Starting from the last two quarters of fiscal year 2005 we have generally seen a steady increase in the sales of our Travado IBUS. During fiscal year 2007 and the first six months of fiscal year 2008 our sales have consisted entirely of Travado IBUS™ products.

Basis of Presentation

The accompanying financial statements have been prepared by National Scientific Corporation (“NSC” or the “Company” or “We”), without audit, and reflect all adjustments that are, in the opinion of management, necessary for a fair statement of the results for the interim periods. The statements have been prepared in accordance with generally accepted accounting principles for interim financial reporting and Securities and Exchange Commission regulations. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to such rules and regulations. In the opinion of management, the financial statements reflect all adjustments (of a normal and recurring nature) that are necessary for a fair presentation of the financial position, results of operations and cash flows for the interim periods.

[Table of Contents](#)

These financial statements should be read in conjunction with the financial statements and notes included in the Company's annual report on Form 10-KSB for the fiscal year ended September 30, 2007 and the Company's quarterly report on Form 10-QSB for the fiscal period ended December 31, 2007.

The results of operations for the six months ended March 31, 2008 are not necessarily indicative of the results to be expected for the entire fiscal year.

Going Concern

The financial statements have been prepared on the basis that the Company will continue as a going concern, which assumes that adequate sources of financing will be obtained as required and that our assets will be realized and liabilities settled in the ordinary course of business. Accordingly, the financial statements do not include any adjustments related to the recoverability of assets and classification of assets and liabilities that might be necessary should we be unable to continue as a going concern.

The Company's ability to continue as a going concern is contingent upon its ability to attain profitable operations and secure financing. There can be no assurance that additional financing will be available to us when needed or, if available, that it can be obtained on commercially reasonable terms. If we are not able to continue as a going concern, we would likely be unable to realize the carrying value of our assets reflected in the balances set out in our financial statements. Our auditors have expressed substantial doubt about the Company's ability to continue as a going concern.

We continue to focus our efforts on improving overall liquidity through identifying new business opportunities within the areas of our core competencies of wireless security systems, reducing operating expenses, and limiting cash commitments for future capital investments and new asset development. We have continued to restrict new capital investment and new asset development, limiting projects to those representing the best opportunities we can find for near term revenue growth in the transportation sector. Additionally, we continue to evaluate operating expenses in an effort to reduce or eliminate costs not required for us to operate effectively. We may elect to negotiate with some of our creditors to reduce or restructure our debt obligations, for example with our larger Note holders, although we cannot be sure of the outcomes of such negotiations. We also in the past have chosen to compensate some consultants and some staff using equity, and also to reduce our debt by allowing staff to convert any accrued back pay to equity, and we are likely to continue this practice in the near term to improve liquidity.

The sale or issue of additional equity would likely have a dilutive effect on existing shareholders, if it were to occur. No assurance can be given that we will be able to obtain a new source of capital on terms that are acceptable to us. If we are unable to obtain new capital, we may be forced to subject ourselves to bankruptcy, reorganization, liquidation, dissolution or similar proceeding.

Use of Estimates

In preparing financial statements in conformity with generally accepted accounting principles, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenues and expenses during the reported period. Actual results could differ from those estimates.

Revenue Recognition

The Company recognizes revenue when persuasive evidence of an arrangement exists, the sales price is fixed or determinable, collection is reasonably assured and delivery of products has occurred or services have been rendered. Accordingly, the Company recognizes revenues upon shipment of product to customers.

Fair Value of Financial Instruments

The Company's financial instruments consist of cash and cash equivalents, accounts receivables, other receivables, accounts payable and accrued liabilities and notes payable. Unless otherwise noted, it is management's opinion that the Company is not exposed to significant interest, currency or credit risks arising from these financial instruments. The fair value of these financial instruments approximates their carrying values due to their short duration, unless otherwise noted or their market interest rate.

Earnings per Share

Statement of Financial Accounting Standards No. 128, "Earnings per Share," ("SFAS 128") provides for the calculation of Basic and Diluted earnings per share. Basic earnings per share includes no dilution and is computed by dividing income available to common shareholders by the weighted average number of common shares outstanding for the period. Diluted earnings per share reflect the potential dilution of securities that could share in the earnings of the Company calculated using the treasury stock method.

Stock-Based Compensation

Effective October 1, 2006, the Company adopted the fair value recognition provisions of Statement of Financial Accounting Standards No. 123 (revised 2004), "Share-Based Payment" ("SFAS 123R"), using the modified prospective transition method and therefore the Company has not restated its results for prior periods. Under this method, compensation cost recognized in the six months ended March 31, 2008 and 2007 include compensation cost for all share-based payments, based on the grant-date fair value estimated in accordance with the provisions of SFAS 123R. All stock based compensation awards were fully vested as of October 1, 2006.

We estimate fair value using the Black-Scholes option-pricing model. Assumptions used to estimate the compensation expense are determined as follows:

- Expected term is determined using a weighted average of the contractual term and vesting period of the award;
- Expected volatility is measured using the average of historical daily changes in the market price of the Company's common stock over the period equal to their expected term;
- Risk-free interest rate is equivalent to the implied yield on U.S. Treasury bills with a remaining maturity equal to the expected term of the awards; and
- Forfeitures are based on the history of cancellations of similar awards granted by the Company and management's analysis of potential forfeitures.

Recent Accounting Pronouncements

In September 2006, the FASB issued SFAS No. 157, "Fair Value Measurements," which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. SFAS No. 157 is effective for fiscal years beginning after November 15, 2007. We do not expect SFAS No. 157 will have a material effect on our financial statements.

In February 2007, the FASB issued SFAS No. 159, "The Fair Value Option for Financial Assets and Financial Liabilities" ("SFAS 159"), which is effective for fiscal years beginning after November 15, 2007. This Statement permits entities to choose to measure many financial instruments and certain other items at fair value. The objective is to improve financial reporting by providing entities with the opportunity to mitigate volatility in reported earnings caused by measuring related assets and liabilities differently without having to apply complex hedge accounting provisions. The Company is currently evaluating the impact of SFAS 159 on its financial statements, but does not expect this new accounting pronouncement to have a material impact.

[Table of Contents](#)

In June 2007, the FASB ratified EITF 06-11 “Accounting for the Income Tax Benefits of Dividends on Share-Based Payment Awards” (“EITF 06-11”). EITF 06-11 provides that tax benefits associated with dividends on share-based payment awards be recorded as a component of additional paid-in capital. EITF 06-11 is effective, on a prospective basis, for fiscal years beginning after December 15, 2007. We do not expect EITF 06-11 will have a material impact on our financial statements.

In December 2007, the FASB issued SFAS No. 160 “Noncontrolling Interests in Consolidated Financial Statements-an amendment of ARB No. 51”. SFAS 160 establishes accounting and reporting standards for the noncontrolling interest in a subsidiary and for the deconsolidation of a subsidiary. The guidance will become effective for the fiscal year beginning after December 15, 2008. The Company does not expect SFAS 160 will have a material impact on our financial statements.

In December 2007, the FASB issued SFAS No. 141 (Revised) “Business Combinations”. SFAS 141 (Revised) establishes principles and requirements for how the acquirer of a business recognizes and measures in its financial statements the identifiable assets acquired, the liabilities assumed, and any noncontrolling interest in the acquiree. The statement also provides guidance for recognizing and measuring the goodwill acquired in the business combination and determines what information to disclose to enable users of the financial statements to evaluate the nature and financial effects of the business combination. The guidance will become effective for the fiscal year beginning after December 15, 2008. The Company does not expect this new accounting pronouncement to have a material impact on our financial statements.

2. Issuance of Common Stock

On February 20, 2008 the Company issued 52,356 of its restricted common shares to Greg Szabo, a director, for board services for the quarter ended March 31, 2008 at the average closing price of the Company’s stock, during the previous quarter, of \$0.0191.

3. Stock-Based Compensation

Stock Options

On October 1, 2006, the Company adopted the fair value recognition provisions of SFAS 123R. Prior to October 1, 2006, the Company accounted for share-based payments under the recognition and measurement provisions of APB 25, and related Interpretations, as permitted by SFAS 123. In accordance with APB 25, no compensation cost was required to be recognized for options granted that had an exercise price equal to the market value of the underlying common stock on the date of grant.

The Company adopted the SFAS 123R method whereby, compensation cost recognized in the six months ended March 31, 2008 and 2007 includes compensation cost for all share-based payments, based on the grant-date fair value estimated in accordance with the provisions of SFAS 123R. All stock based compensation awards were fully vested as of October 1, 2006; therefore, the results for prior periods have not been restated.

As of March 31, 2008, we have a stock-based compensation plan initially adopted in 2000 wherein officers and employees were granted stock options. Under the 2000 Stock Option Plan, the purchase price must be at least 100% of the fair market value of our common stock (if the option is an incentive stock option), or at least 25% of the fair market value of our common stock at the time the option is granted (if the option is a nonqualified grant), or such higher price as may be determined by the Board of Directors at the time of grant. If however, an incentive stock option is granted to an individual who would, immediately before the grant, directly or indirectly own more than 10% of the total combined voting power of all our classes of stock, the purchase price of the shares of common stock covered by such incentive stock option may not be less than 110% of the fair market value of such shares on the day the incentive stock option is granted. As the price of the Company’s common stock is currently quoted on the OTC Bulletin Board, the fair market value of the common stock underlying options granted under the 2000 Stock Option Plan shall be the last closing sale price of the common stock on the day the options are granted. If there is no market price for the common stock, then our Board of Directors may, after taking all relevant facts into consideration, determine the fair market value of our common stock.

Table of Contents

Our board of directors adopted the 2000 Stock Option Plan effective January 1, 2001. Our stockholders formally approved the 2000 Stock Option Plan on February 14, 2001.

As of March 31, 2008, we have issued options to purchase an aggregate of 5,251,756 shares of our common stock, under the plan, leaving a balance of 1,748,244 available for grant. Also as of March 31, 2008, 5,251,756 options are exercisable and 5,251,756 are vested. We have reserved the right to issue a total of 7,000,000 shares of our common stock for issuance under the 2000 Stock Option Plan.

During the six months ended March 31, 2008, the following options were granted:

On October 9, 2007, 20,000 options were granted to Greg Szabo, a director, for board services. The weighted average grant date fair value of these options was \$0.008. Stock based compensation of \$158 was recognized in the financial statements using the Black-Scholes option pricing model value on the grant date. The options have a life of ten years.

On November 14, 2007, 225,000 options were granted to Graham Clark, a director. The compensation committee as an incentive to retain key staff members approved this grant. The weighted average grant date fair value of these options was \$0.016. Stock based compensation of \$3,579 was recognized in the financial statements using the Black-Scholes option pricing model value on the grant date. The options have a life of ten years.

On November 14, 2007, 100,000 options were granted to Greg Szabo, a director. The compensation committee as an incentive to retain key staff members approved this grant. The weighted average grant date fair value of these options was \$0.016. Stock based compensation of \$1,591 was recognized in the financial statements using the Black-Scholes option pricing model value on the grant date. The options have a life of ten years.

On November 14, 2007, 100,000 options were granted to Michael Grollman, a director. The compensation committee as an incentive to retain key staff members approved this grant. The weighted average grant date fair value of these options was \$0.016. Stock based compensation of \$1,591 was recognized in the financial using the Black-Scholes option pricing model value on the grant date. The options have a life of ten years. Also, on November 14, 2007, in lieu of taking a larger grant, 450,000 options granted to Michael Grollman on December 1, 2000 at an exercise price of \$1.84 were canceled and exchanged for 450,000 options having an exercise price of \$0.03. \$4,785, was recognized as the incremental compensation cost of the modified award in the financial statements.

On January 14, 2008, 20,000 options were granted to Greg Szabo, a director, for board services. The weighted average grant date fair value of these options was \$0.0189. Stock based compensation of \$379 was recognized in the financial statements using the Black-Scholes option pricing model value on the grant date. The options have a life of ten years.

During the six months ended March 31, 2008, no options were exercised.

As required by SFAS 123R, the fair value of each grant is estimated on the date of the grant using the Black-Scholes option pricing method with the following assumptions to value options for the six months ended March 31, 2008 and 2007:

	<u>2008</u>	<u>2007</u>
Risk - free interest rate	3.06% to 4.23%	4.46% to 4.65%
Expected life (years)	5	10
Expected volatility	116.0% to 124.9%	91.4% to 181.8%
Expected dividends	None	None
Forfeitures assumed	None	None
Weighted average grant date fair value	\$0.005 to \$0.018	\$0.0220 to \$0.0599

[Table of Contents](#)

The following table summarizes the stock option activity during the first six months of fiscal year 2008:

	<u>Number of Shares</u>	<u>Weighted Average Exercise Price</u>	<u>Weighted Average Remaining Contractual Term (1)</u>	<u>Aggregate Intrinsic Value (2)</u>
Options Outstanding, September 30, 2007	4,786,756	\$ 0.74	6.16	
Granted	915,000	0.03		
Exercised	–	–		
Forfeited or expired	(450,000)	1.84		
Options Outstanding, March 31, 2008	<u>5,251,756</u>	<u>\$ 0.43</u>	<u>5.70</u>	<u>\$ –</u>
Options Exercisable March 31, 2008	<u>5,251,756</u>	<u>\$ 0.43</u>	<u>5.70</u>	<u>\$ –</u>

- (1) Remaining contractual term is presented in years
- (2) The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the closing price of our common stock as of March 31, 2008, for those awards that have an exercise price currently below the closing price as of March 31, 2008. Awards with an exercise price above the closing price of \$0.010 as of March 31, 2008 are considered to have no intrinsic value.

Warrants

During the six months ended March 31, 2008, no awards were granted, no share purchase warrants were exercised, and no warrants were forfeited.

The following assumptions were utilized to value warrants during the six months ended March 31, 2007:

	<u>2007</u>
Risk - free interest rate	4.60% to 4.82%
Expected life (years)	2 to 5
Expected volatility	83.5% to 181.2%
Expected dividends	None
Forfeitures assumed	None
Weighted average grant date fair value	\$0.016

[Table of Contents](#)

The following table summarizes the warrant activity during the first six months of fiscal year 2008:

	Number of Shares	Weighted Average Exercise Price	Weighted Average Remaining Contractual Term (1)	Aggregate Intrinsic Value (2)
Warrants Outstanding, September 30, 2007	17,714,197	\$ 0.17	1.56	
Granted	—	—	—	
Exercised	—	—	—	
Cancelled or expired	—	—	—	
Warrants Outstanding, March 31, 2008	17,714,197	\$ 0.17	1.31	\$ —

(1) Remaining contractual term is presented in years.

(2) The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the closing price of our common stock as of March 31, 2008, for those awards that have an exercise price currently below the closing price as of March 31, 2008. Awards with an exercise price above the closing price as of March 31, 2008 of \$0.010 are considered to have no intrinsic value.

4. Trade Receivables

Trade receivables are net of reserves:

	March 31, 2008 (Unaudited)	September 30, 2007 (Audited)
Trade receivables	\$ 47,392	\$ 6,216
Less: reserves	—	—
	<u>\$ 47,392</u>	<u>\$ 6,216</u>

Trade Receivables of \$47,392 at March 31, 2008 included factored invoices totaling \$21,912. Trade Receivables of \$6,216 at September 30, 2007 included factored invoices totaling \$2,602.

5. Inventory, net

Inventories, primarily purchased parts and finished goods, are stated at the lower of cost or market values. Cost is determined on a FIFO (first-in, first-out) basis.

Inventory, net consisted of the following at March 31, 2008 and September 30, 2007:

	March 31, 2008 (Unaudited)	September 30, 2007 (Audited)
Inventory, gross	\$ 15,340	\$ 22,900
Less: reserve for obsolescence	—	—
Inventory, net	<u>\$ 15,340</u>	<u>\$ 22,900</u>

[Table of Contents](#)

6. Accrued Expenses

Accrued expenses consisted of the following at March 31, 2008 and September 30, 2007:

	March 31, 2008	September 30, 2007
	(Unaudited)	(Audited)
Salaries and vacation pay - current management and staff	\$ 694,307	\$ 575,727
Salaries and vacation pay - former employee	29,375	29,375
Payroll taxes for accrued back pay	50,112	40,781
Interest	187,359	156,271
Employee stock retainage pool	50,250	50,250
Other liabilities	20,881	30,996
	<u>\$ 1,032,284</u>	<u>\$ 883,400</u>

7. Notes Payable and Long-Term Debt

As of March 31, 2008 and September 30, 2007, long-term debt consisted of the following notes payable:

	March 31, 2008	September 30, 2007
	(Unaudited)	(Audited)
Non-interest bearing note payable on demand; unsecured; repayment may be made by the Company with either cash or its restricted common stock or a combination of cash and stock	\$ 43,250	\$ 43,250
8% note payable to a related party; unsecured; principal and interest payable on demand	144,876	161,300
12% note payable; secured; payable on demand	11,625	11,625
12% note payable; secured; payable on demand	20,000	20,000
8% note payable; unsecured; principal payable in full in November 2010; with semi-annual interest payments in May and November	175,000	175,000
6% note payable; unsecured; payable on demand with 30 days prior notice	5,000	6,000
	<u>399,751</u>	<u>417,175</u>
Less:		
Current portion of long term debt	(224,751)	(242,175)
Discount	(26,660)	(31,820)
Beneficial conversion feature	(5,132)	(6,125)
Long-term debt, net of current portion	<u>\$ 143,208</u>	<u>\$ 137,055</u>

[Table of Contents](#)

The aggregate maturities of long-term debt were as follows:

	March 31, 2008 (Unaudited)	September 30, 2007 (Audited)
2008	224,751	242,175
2009	—	—
2010	175,000	175,000
	<u>\$ 399,751</u>	<u>\$ 417,175</u>

8. Earnings Per Share

Statement of Financial Accounting Standards No. 128, "Earnings per Share," provides for the calculation of Basic and Diluted earnings per share. Basic loss per share includes no dilution and is computed by dividing loss available to common shareholders by the weighted average number of common shares outstanding for the period.

The following table reconciles weighted average shares outstanding to amounts used to calculate basic and diluted earnings per share for the three and six months ended March 31, 2008 and 2007.

	Three months ended March 31,		Six months ended March 31,	
	2008	2007	2008	2007
Net (loss)	\$ (124,923)	\$ (176,741)	\$ (216,819)	\$ (299,384)
Weighted average shares:				
Average shares outstanding	122,303,826	102,116,638	122,230,098	100,595,808
Effect of diluted shares	—	—	—	—
Average shares outstanding adjusted for dilutive effect	<u>122,303,826</u>	<u>102,116,638</u>	<u>122,230,098</u>	<u>100,595,808</u>
(Loss) per share - basic	\$ (0.00)	\$ (0.00)	\$ (0.00)	\$ (0.00)
(Loss) per share - diluted	<u>\$ (0.00)</u>	<u>\$ (0.00)</u>	<u>\$ (0.00)</u>	<u>\$ (0.00)</u>

Incremental common shares (not included in denominator of diluted earnings per share because of their anti-dilutive nature):

	March 31, 2008	March 31, 2007
Options	5,251,756	4,346,756
Warrants	17,714,197	18,354,197
Potential common equivalents	<u>22,965,953</u>	<u>22,700,953</u>

9. Subsequent Events

None.

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

SAFE HARBOR STATEMENT

Statements contained herein that are not historical fact may be forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We use words and phrases such as "should be," "will be," "believes," "expects," "anticipates," "plans," "intends," "may" and similar expressions to identify forward-looking statements. Forward-looking statements are made based upon our belief as of the date that such statements are made. These forward-looking statements are based largely on our current expectations and are subject to a number of risks and uncertainties, many of which are beyond our control. You should not place undue reliance on these forward-looking statements, which apply only as of the date of such documents. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including the risks faced by us described above and elsewhere in this report. This report should be read in conjunction with the financial statements and other information included in the Company's annual report on Form 10-KSB for the fiscal year ended September 30, 2007, which is incorporated herein by reference as well as previous Form 10-QSB reports covering the period ended December 31, 2007.

General

The following is management's discussion and analysis of certain significant factors affecting our financial position and operating results during the periods included in the accompanying condensed financial statements. Except for the historical information contained herein, the matters set forth in this report are forward-looking statements.

Overview

Our primary business involves the research, development, manufacture, and sale of hardware and software computer based products and devices that span a range of industries. The majority of our products are mobile computers configured as digital video recording devices with location-determining and tracking capabilities. These devices typically use small powerful mobile computers, in conjunction with equally small portable radios to establish, record and report the physical location of people and objects to which these devices are attached. Our location technologies typically use Global Positioning System (GPS) technology to determine position. They also use small computers in conjunction with video cameras and other sensors to record incidents on mobile systems, especially school buses. We also have other products that use non-GPS technology to establish and then report position. We refer to our location-determining devices as our location tracking products, or as location tools products.

Our primary customer focus for these location-tracking products is the safety market, related in many cases to the safety of school age children. Our products and services help our customers keep better track of their children. Our products are also used to keep track of adults, and as well to track and monitor physical assets, such as equipment or vehicles. Our location tracking products are often sold as an integrated system, by using them in conjunction with software that screen displays maps and other pertinent information.

Prior to 2002 we developed electronic component products, some of which are used in radio equipment, and some of which have other applications in the electronics field, such as in the memory systems of personal computers. Many of these electronic component products have been issued U.S. patents. We focused extensively on developing these products and patenting them from 1996 through early 2002, with the objective of licensing these products to other electronic companies. In early 2002, due to market conditions, our focus shifted away from further development of our electronic component products, but we continue to explore licensing opportunities for our component products.

[Table of Contents](#)

Since 2002, we began to focus on applications of electronic devices in the location tools market. From 2002 through 2005, we were primarily engaged in product development and market research and testing. During fiscal year 2005, the Company increased its focus on its Travado IBUS™, a location product that entered the market in March 2005. Starting from the last two quarters of fiscal year 2005, we have generally seen a steady increase in the sales of our Travado IBUS. During fiscal year 2007 and the first half year of fiscal year 2008 our sales have consisted entirely of Travado IBUS™ products.

Three Months Ended March 31, 2008 Compared to Three Months Ended March 31, 2007

Revenues

Revenues improved by approximately 236% to \$156,216 for the three months ended March 31, 2008 from \$46,500 for the three months ended March 31, 2007 largely due to a 470% increase in the number of Travado IBUS™ products sold.

Gross Profit

Gross profit increased to \$73,183 for the three months ended March 31, 2008 from \$24,990 for the three months ended March 31, 2007 primarily due to higher volume of Travado IBUS™ sales. However, gross profit margin as a percentage of revenues, decreased from 54% to 47% in the three months ended March 31, 2008 mainly because the average unit selling price of 81% of our unit sales in the 2008 quarter, were priced lower according to a 2006 bid which expires on April 30, 2008.

Salaries and Benefits

Salaries and benefits, of administration and marketing personnel increased to \$71,055 for the three months ended March 31, 2008 from \$62,529 for the three months ended March 31, 2007. The increase is mainly attributable to the hiring of sales and manufacturing part-time staff.

Research and Development

Research and development expenditures of \$41,457 for the three months ended March 31, 2008 remained almost flat when compared to \$40,834 for the three months ended March 31, 2007. The Company will continue to explore innovative ways to take its technology expertise and products to market, across its entire portfolio of semiconductor and location electronics related devices.

Stock Compensation

Stock compensation for the three months ended March 31, 2008 totaled \$14 compared to \$4,931 for the three months ended March 31, 2007. The decrease in the quarter ended March 31, 2008 is mainly attributable to an adjustment of \$1,600 reducing the fair value of option awards recorded in the prior quarter.

Other Expenses

Other expenses totaled \$62,608 in the three months ended March 31, 2008 compared to \$34,330 in the three months ended March 31, 2007. The increase resulted primarily from increased, factors' fees of approximately \$4,000, insurance costs of approximately \$3,000, delivery costs of approximately \$1,000, principal accountant fees of approximately \$3,000, professional fees of approximately \$3,000, shareholders' meeting expenses not incurred in the comparative prior quarter of approximately \$4,000, selling expenses of approximately \$1,000, marketing and trade show expenses of approximately \$2,000 and warranty expenses of approximately \$6,000 for the set up of a warranty reserve and the upgrade of customer systems.

[Table of Contents](#)

Other Income

Other income of \$25,000 in the three months ended March 31, 2007 consisted of the reversal to revenue of an unclaimed accrued expense related to a fully amortized investment. There was no other income in the three months ended March 31, 2008.

Interest Expense

Interest expense of \$21,772 during the three months ended March 31, 2008 decreased from \$82,907 during the three months ended March 31, 2007, primarily because the second quarter of fiscal year 2007 included a one time charge of \$66,000 representing the value of stock issued to settle a dispute regarding timing of interest payment on a note.

Amortization of Deferred Financing Costs

Amortization of deferred financing costs for the three months ended March 31, 2008 remained flat at \$1,200 when compared to the three months ended March 31, 2007.

Six Months Ended March 31, 2008 Compared to Six Months Ended March 31, 2007

Revenues

Revenues improved by approximately 101% to \$371,755 for the six months ended March 31, 2008 from \$184,716 for the six months ended March 31, 2007 largely due to a 142% increase in the number of Travado IBUS™ products sold.

Gross Profit

Gross profit increased to \$165,282 for the six months ended March 31, 2008 from \$91,231 for the six months ended March 31, 2007. The higher gross profit dollars are attributable to the higher sales volume. However, gross profit margin as a percentage of revenues, decreased from 49% to 45% in the six months ended March 31, 2008 mainly because the average unit selling price of 32% of our unit sales in the 2008 fiscal period, were priced lower according to a 2006 bid which expires on April 30, 2008.

Salaries and Benefits

Salaries and benefits, of administration and marketing personnel increased to \$137,293 for the six months ended March 31, 2008 from \$133,851 for the six months ended March 31, 2007. The increase is mainly attributable to the hiring of sales and manufacturing part-time staff.

Research and Development

Research and development expenditures of \$84,708 for the six months ended March 31, 2008 remained almost flat when compared to \$84,287 for the six months ended March 31, 2007. The Company will continue to explore innovative ways to take its technology expertise and products to market, across its entire portfolio of semiconductor and location electronics related devices.

Stock Compensation

Stock compensation for the six months ended March 31, 2008 totaled \$14,319 compared to \$7,931 for the six months ended March 31, 2007. The increase in the half-year ended March 31, 2008 is mainly attributable to the fair value of option awards used as incentives to retain key staff members

[Table of Contents](#)

Other Expenses

Other expenses totaled \$98,761 in the six months ended March 31, 2008 compared to \$69,273 in the six months ended March 31, 2007. The increase resulted primarily from increased, factors' fees of approximately \$2,000, insurance costs of approximately \$3,000, delivery costs of approximately \$3,000, principal accountant fees of approximately \$6,000, professional fees of approximately \$1,000, shareholders' meeting expenses not incurred in the comparative prior quarter of approximately \$2,000, selling expenses of approximately \$3,000, marketing and trade show expenses of approximately \$2,000 and warranty expenses of approximately \$9,000 for the set up of a warranty reserve and the upgrade of customer systems. The increases were somewhat offset by decreases in rent and travel expenses.

Other Income

Other income of \$25,740 in the six months ended March 31, 2007 consisted primarily of the reversal to revenue of an unclaimed accrued expense related to a fully amortized investment. There was no other income in the six months ended March 31, 2008.

Interest Expense

Interest expense of \$44,620 during the six months ended March 31, 2008 decreased from \$118,613 during the six months ended March 31, 2007, primarily because the second quarter of fiscal year 2007 included a one time charge of \$66,000 representing the value of stock issued to settle a dispute regarding timing of interest payment on a note and approximately \$10,000 of beneficial conversion feature expense not incurred in the first six months of fiscal year 2008.

Amortization of Deferred Financing Costs

Amortization of deferred financing costs for the six months ended March 31, 2008 of \$2,400 was unchanged when compared to the six months ended March 31, 2007.

Liquidity and Capital Resources

We have financed our operations primarily through the sale of common stock and warrants in the public and private market, and to a very limited extent and only just recently, through the sale of our products. The Company has recently initiated product-marketing efforts after several years of research and development and has not yet reached break even in terms of both cash flow and profitability.

As of March 31, 2008, the Company had cash and cash equivalents of \$2,322, total current assets of \$77,687 and total liabilities of \$1,618,400 including notes payable of \$399,751 gross of debt discount and beneficial conversion feature, accounts payable of \$196,245, accrued expenses of \$1,032,284 and amounts due to factors of \$21,912. The accounts payables total of \$196,245 included invoices of approximately \$73,000 that are aged over three years. The accrued expenses total of \$1,032,284 included approximately \$694,307 of unpaid wages and vacation pay.

Cash used in operations was \$85,451 for the six months ended March 31, 2008 compared to \$112,431 for the six months ended March 31, 2007.

Net cash provided by financing activities was \$1,886 for the six months ended March 31, 2008 compared to \$82,980 for the six months ended March 31, 2007. The higher financing activities in the six months ended March 31, 2007 mainly reflects net proceeds from the issuance of common stock.

[Table of Contents](#)

We believe that our current cash position as of March 31, 2008, including cash funds arising from the exercise of outstanding options, from equity placement sales and other capital raising efforts, loans from officers, product sales, and continued aggressive expense management to be sufficient to continue operations for the next twelve months. We also believe that we may be able to reduce outstanding liabilities through negotiations with our creditors, or possibly negotiate to extend the payment schedule for these debts. In the event these approaches do not provide us with adequate working capital, we may be required to further curtail or reduce our development activities, seek alternative funding sources, or seek protection under reorganization laws. The Company's ability to continue as a going concern is contingent upon its ability to attain profitable operations and secure financing. There can be no assurance that additional financing will be available to us when needed or, if available, that it can be obtained on commercially reasonable terms. If we are not able to continue as a going concern, we would likely be unable to realize the carrying value of our assets reflected in the balances set out in our financial statements. Our auditors have expressed substantial doubt about the Company's ability to continue as a going concern.

Other Subsequent Events

As of March 31, 2008, the company had a backlog of orders for its Travado IBUS™ systems of approximately \$ 126,000. As of the date of this report, most of this backlog had been shipped, and a current backlog of approximately \$ 97,000 existed. The Company has noted in the past few years that sales in the June-ending quarter for its products tend to be stronger than in the March-ending quarter. This is typically due to government fiscal year-end effects, and on imminent business that is likely to arise from the good current sales pipeline. The company therefore, has reason to believe that the current quarter would continue to support that seasonal up-trend, although management believes there is still significant uncertainty on any final results for the current quarter.

In order to support this trend and allow for possible growth in revenues, the Company is exploring various avenues for a possible new debt and debt consolidation over the course of the next several months of up to \$500,000 although no firm decisions in this area have been made by its board, and there is no assurance that such financing would be available on acceptable terms. Part of this effort may include an expansion of the conversion of employee back pay debt to a significant amount of restricted company common stock, at then-current market prices, which has previously been authorized by its board. Also, early payoff of some large notes to creditors outside of the Company may be considered.

After providing lawful notice, the annual meeting of the stockholders of National Scientific Corporation was held at the Scottsdale Thunderbird Suites, 7515 East Butherus Drive, Scottsdale, Arizona, on April 30, 2008, at 10 o'clock, a.m. Full minutes of the meeting are available at the Company's offices in Scottsdale, a summary is offered here. A shareholder list was presented, showing that as of the March 7, 2008 record date, 122,332,913 shares of Common Stock were issued and outstanding, all of which were entitled to be voted at the meeting. A quorum was established. The first matter voted on was Proposal No. 1, the election of directors. As provided in the Proxy Statement, Michael A. Grollman, Graham L. Clark, and Gregory Szabo have been nominated by the Board of Directors for election as members of the Board of Directors of the Company for a term of office expiring at the 2009 Annual Meeting of Shareholders, or until a successor is elected and qualified. Proposal No. 2, as described in the Proxy Statement, said that Semple, Marchal & Cooper, LLP should be ratified for appointment as independent auditor for National Scientific Corporation for the fiscal year ending September 30, 2008.

The voting on the Proposals took place after appropriate motions. After the votes were counted, the Inspector of Elections gave her report as follows: "I have counted the ballots and, of the 85,776,539 shares of Common Stock present in person or by proxy and entitled to be voted at this meeting, at least 84,748,716 votes were cast FOR the election of Michael A. Grollman, Graham L. Clark, and Gregory Szabo as members of the Board of Directors of the Company, which is more than a majority of the shares represented at this meeting. With respect to Proposal No.2, 84,155,808 shares were cast FOR Proposal No. 2. Thus, persons holding a majority of the outstanding shares of the Company's Common Stock voted for the adoption of Proposal No. 2." The motions were determined to have passed, and shortly thereafter, the formal meeting was adjourned.

[Table of Contents](#)

After the meeting, management presented a brief informal review of operations to any interested shareholders, and answered questions, after a safe harbor disclosure was reviewed. Among other things, management underlined a goal for the next year of attempting to continue its growth in revenues while maintaining strong control over expense growth. Possible efforts to reduce debt on the balance sheet were discussed; these included the continuing efforts to attempt to get debt holders to accept equity in place of their debt, including some older vendors, and some employees. Refinancing of some existing debt was also discussed. A possible program to reduce outstanding shares of common stock through a reserve split was also discussed, although this was not a program management announced, just a possible direction for sometime in the future. Some new directions in product R&D were discussed as well, including smaller and more reliable devices for future bus sales. No specifics were disclosed, however, and no demonstrations given. After this the discussion ended.

ITEM 3. Quantitative and Qualitative Disclosures About Market Risk

Not required under Regulation S-K for “smaller reporting companies.”

Item 4T. Controls and Procedures

Our management has responsibility for establishing and maintaining adequate internal control over financial reporting for us. Our management uses a framework for establishing these internal controls. This framework includes review of accounting detailed records on at least a quarterly basis by senior officers of National Scientific. This review process includes review of significant accounting records and source documents, such as general journal entry records, accounts payable records, and monthly bank statement reconciliations. Documentary records are kept of this review process.

The Company carried out an evaluation, under the supervision and with the participation of the Company’s management, including its Chief Executive Officer and Acting Chief Financial Officer, of the effectiveness, as of March 31, 2008, of the design and operation of the Company’s disclosure controls and procedures pursuant to Exchange Act Rule 13a-15. Based upon that evaluation, the Chief Executive Officer and Acting Chief Financial Officer concluded that the Company’s disclosure controls and procedures are effective.

There have been no changes in our internal control over financial reporting during the period ended March 31, 2008 that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

Our management believes that upon significant future growth in the number of accounting transactions we process, perhaps within the next year, additional review and enhancement of internal controls will be required. Our management is planning to assign additional staff resources to assist with support for growth in the internal controls area when the increase in transaction velocity dictates this as a prudent step in order to maintain our effective level of internal controls.

Our external auditors, for the year ended September 30, 2007, Semple, Marchal & Cooper, LLP have not issued an attestation report on management’s assessment of the Company’s internal control over financial reporting, as it is not yet required since the Company has less than \$75 million in “public float.”

PART II - OTHER INFORMATION

Item 1. Legal Proceedings

The Company is involved in legal actions in the ordinary course of its business, including those outlined in the Company’s annual report on Form 10-KSB for the fiscal year ended September 30, 2007. Although the outcome of any such legal actions cannot be predicted, in the opinion of management, there are no legal proceedings pending or asserted against or involving the Company the net outcome of which are likely to have a material adverse effect upon the financial position or results of operations of the Company.

Item 1A. Risk Factors

Carefully consider the risk factors set forth in the Annual Report on Form 10-KSB for the fiscal year ended September 30, 2007 that could materially affect our business, financial condition or future results. The risk factors set forth in our Annual Report on Form 10-KSB for the fiscal year ended September 30, 2007 have not materially changed.

Item 2. Unregistered Sale of Equity Securities and Use of Proceeds

None.

Item 3. Defaults Upon Senior Securities.

None.

Item 4. Submission of Matters to a Vote of Security Holders.

None.

Item 5. Other Information.

None.

Item 6. Exhibits.

Exhibit Number	Description
13	Form 10-KSB Annual Report For The Fiscal Year Ended September 30, 2007 ⁽¹⁾
31	Certification Pursuant to Section 302 of the Sarbanes-Oxley Act
32	Certification Pursuant to Section 906 of the Sarbanes-Oxley Act

(1) Filed on or around December 31, 2007, on Form 10-KSB.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

NATIONAL SCIENTIFIC CORPORATION

Date: May 15, 2008

By: /s/ Michael A. Grollman
Michael A. Grollman
Director, Chief Executive Officer, Acting Chief
Financial Officer and Chairman

By: /s/ Graham L. Clark
Graham L. Clark
Director, President, and Secretary

By: /s/ Gregory Szabo
Gregory Szabo
Director

EXHIBIT 31

Certification of the Chief Executive Officer and Acting Chief Financial Officer

I, Michael A. Grollman, certify that:

1. I have reviewed this quarterly report on Form 10-Q of National Scientific Corporation;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:
 - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

/s/ Michael A. Grollman

Michael A. Grollman
Chairman, Chief Executive Officer,
and Acting Chief Financial Officer
May 15, 2008

EXHIBIT 32

**Certification of Chief Executive Officer and
Acting Chief Financial Officer**

The undersigned, Michael A. Grollman, Chairman of the Board of Directors, Chief Executive Officer and Acting Chief Financial Officer of National Scientific Corporation (the "Company"), has executed this certification in connection with the filing with the Securities and Exchange Commission of the Company's Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2008 (the "Report"). The undersigned hereby certifies that:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2. The information contained in the Report fairly presents, in all material respects, the financial results of operations of the Company.

IN WITNESS WHEREOF, the undersigned has executed this certificate as of the 15th day of May, 2008.

/s/ Michael A. Grollman

Michael A. Grollman
Chairman, Chief Executive Officer,
and Acting Chief Financial Officer

The foregoing certification is being furnished solely pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Section 1350 of Chapter 63 of Title 18 of the United States Code) and is not being filed as part of the Report or as a separate disclosure document.
